Loading...
NPI 1316155500 · Amherst, NY · Neurology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Bela Ajtai is a neurology physician provider located in Amherst, New York. This profile covers 46 Medicare and 20 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Bela Ajtai |
| Address | 3980a Sheridan Dr |
| City | Amherst |
| State | NY |
| ZIP | 14226 |
| Taxonomy | Neurology Physician |
| NPI Enumerated | May 19, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.1M |
| Medicaid | $139.5K |
This provider is heavily Medicare-revenue centric: lifetime Medicare revenue is $4.1M versus Medicaid revenue of $139.5K, indicating Medicare accounts for the overwhelming majority of billed income and that the practice’s operations are primarily anchored in fee-for-service Medicare business. The large gap suggests the provider functions largely in programs and services reimbursed through Medicare rather than Medicaid.
Revenue concentration in Medicare is high: the precomputed top 3 Medicare codes by revenue account for 76.5% of total Medicare revenue. The dominance of J1561, J2350, and J3380 in the Medicare mix implies that a small set of high-revenue infusion/injectable drug codes drives most of the practice’s Medicare income.
Business/service-line implication from the top Medicare codes: the largest Medicare revenue sources are drug infusion and biologic administration codes (J1561, J2350, J3380), alongside multiple chemotherapy/infusion administration and infusion-add-on codes (96413, 96365, 96366, 96415). This mix indicates the provider operates a high-volume infusion/infusible biologics service line rather than being purely clinic visit–based, with substantial resources devoted to administering injectable biologics and infusions.
Competitive standing nationally on key Medicare drugs is strong for specific codes: J1561 is ranked #2 of 180 providers nationally (99th percentile) and is described as notably above typical national volume, marking the provider as a major national participant for that immune globulin product. J3380 and several infusion-related codes (96413, 96365, 96366, 96415) also rank high in percentiles (95–98th) and are described as notably above typical national volume or extreme outlier, underscoring outsized activity in infusion services relative to peers.
Medicaid billing is concentrated but modest in scale: the precomputed top 3 Medicaid codes by revenue account for 73.3% of total Medicaid revenue, and 99214 alone is 42.5% of Medicaid revenue. Medicaid activity appears more oriented to outpatient evaluation-and-management and infusion initiation (99214 and 96365), suggesting the provider sees Medicaid patients for routine follow-up visits and also provides some infusion services to that population, but overall Medicaid revenue is small relative to Medicare.
State-level competitive posture on Medicaid is typical to modest: for Medicaid, the provider’s 99214 ranks in-state at the 85th percentile (typical, unremarkable volume) and 96365 ranks at the 66th percentile, indicating the provider is a credible but not dominant Medicaid participant in office visits and infusion starts within New York. Several Medicaid drug/infusion codes show typical volumes in-state rather than extreme standing.
Tenure is long-standing: the NPI was enumerated on 2007-05-19 (~19 years ago), indicating nearly two decades of formal registration and continuity, which supports interpretation of the observed high-volume infusion patterns as an established service line rather than a short-term anomaly.
Statistical outliers and notable volume flags emphasize infusion specialization: across Medicare, codes such as J1561 (99th percentile, notably above typical), J3380 (95th percentile, notably above typical), and 96366 (98th percentile, extreme outlier) are repeatedly called out as far above typical national volumes. These labels reinforce that the provider’s practice is an outlier in delivering certain infused biologics and extended infusion services compared with national peers, not merely a routine billing mix.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
46 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 42,560 | $40 | $1.6M |
| J2350 | Injection, ocrelizumab, 1 mg | 22,810 | $50 | $1M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 28,520 | $20 | $456.2K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 11,710 | $30 | $304.3K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 6,400 | $30 | $217.6K |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 8,500 | $10 | $110.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 810 | $100 | $77.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 840 | $50 | $39.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 370 | $90 | $32.6K |
| 70551 | The provider uses magnetic resonance imaging, or MRI, to examine the brain and brain stem. The provider does not administer contrast for this exam. | 170 | $140 | $24K |
Showing 1–10 of 46
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
46 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2350 | 2 | 10 | 14,700 | $50 | $1.4M |
| J3380 | 3 | 30 | 13,500 | $20 | $270.1K |
| J0129 | 24 | 40 | 6,830 | $30 | $268.9K |
| J1561 | 1 | 40 | 3,100 | $40 | $234.9K |
| J1745 | 6 | 50 | 2,980 | $30 | $124.1K |
| J3032 | 1 | 10 | 4,450 | $10 | $53.2K |
| J3490 | 78 | 120 | 60 | $470 | $50.8K |
| 99214 | 4,414 | 30,450 | 90 | $100 | $19K |
| 96413 | 3 | 380 | 110 | $110 | $18.1K |
| 70553 | 291 | 590 | 70 | $160 | $17.5K |
Showing 1–10 of 46
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,910 | $30 | $59.1K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 1,850 | $10 | $22.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 1,370 | $20 | $20.6K |
| 70551 | The provider uses magnetic resonance imaging, or MRI, to examine the brain and brain stem. The provider does not administer contrast for this exam. | 160 | $80 | $13K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 520 | $20 | $10.4K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 1,180 | $10 | $5.9K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 520 | $10 | $3.1K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 1,300 | $1 | $2.6K |
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 210 | $1 | $850 |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 30 | $20 | $510 |
Showing 1–10 of 20
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
20 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96415 | In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the… | 51 | 90 | 260 | $360 | $435.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 64 | 200 | 630 | $150 | $338K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 8,507 | 19,110 | 360 | $70 | $321K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 146 | 430 | 680 | $120 | $299.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,535 | 16,550 | 220 | $90 | $186.8K |
| 70551 | The provider uses magnetic resonance imaging, or MRI, to examine the brain and brain stem. The provider does not administer contrast for this exam. | 167 | 370 | 110 | $180 | $127.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 2,683 | 3,820 | 100 | $130 | $99.7K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 58 | 140 | 290 | $70 | $70.5K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 166 | 250 | 2,570 | $10 | $53.3K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 394 | 1,420 | 300 | $20 | $38.8K |
Showing 1–10 of 20
Other providers in the same ZIP code as Bela Ajtai, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Buffalo Beacon Corporation | NY | Addiction (Substance Use Disorder) Counselor | $0 | $36.9M |
| Buffalo Surgery Center LLC | NY | Ambulatory Surgical Clinic/Center | $348.6K | $1.5M |
| Ambulatory Surgery Center Of Wny | NY | Ambulatory Surgical Clinic/Center | $1.2M | $364.7K |
| Wny Medical Management, LLC | NY | Ambulatory Surgical Clinic/Center | $449.7K | $0 |
| Vijay Iyer | NY | Cardiovascular Disease Physician | $158K | $0 |
| Kenneth Hood | NY | Orthopaedic Surgery of the Spine Physician | $119.7K | $0 |
| Michael Vasquez | NY | Vascular Surgery Physician | $114.7K | $1.2K |
| Wisam Elmalik | NY | Neurology Physician | $69.5K | $15.7K |
| Parkview Health Services, LLC | NY | Long Term Care Pharmacy | $24.4K | $60.1K |
| Scott Nodzo | NY | Orthopaedic Surgery Physician | $79.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.